Currently, a variety of therapeutic interventions have been reported for prevention of programmed hypertension and kidney disease, such as supplementation of NO substrate, ADMA-lowering agents, NO donors, and enhancement of the expression and/or activity of NOS. This evidence concerns the gene NOS2 and Hypertension.